400-920-2911 sales@csnpharm.cn
CAS No.: 210644-62-5
Synonyms: (Z)-SU6668;(Z)-TSU-68;NSC 702827
SU6668 is a cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively).
规格 | 价格 | 促销价格 | 库存 | 数量 |
---|
生物活性
靶点 | c-Kit IC50:0.01µM | Aurora Kinase B IC50:0.047µM | PDGFRβ IC50:0.1µM | Aurora Kinase A IC50:0.85µM | TBK1 IC50:1.4µM | 更多 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00784290 | Hepatocellular Carcinoma | Phase 1 Phase 2 | Completed | - | Japan ... more >> Chiba University Hospital Inohana Chuo-ku Chiba, Chiba, Japan, 260-8670 Collapse << |
NCT00024063 | Breast Cancer ... more >> Colorectal Cancer Gastric Cancer Kidney Cancer Lung Cancer Multiple Myeloma and Plasma Cell Neoplasm Pancreatic Cancer Prostate Cancer Collapse << | Phase 1 | Unknown | - | - |
NCT01465464 | Hepatocellular Carcinoma | Phase 3 | Terminated | - | Japan ... more >> Local Institution Osaka-sayama, Osaka, Japan, 589-8511 Local Institution Chuo-ku, Tokyo, Japan, 104-0045 Local Institution Chiba, Japan, 260-8677 Korea, Republic of Local Institution Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 Local Institution JongNo-Gu, Seoul, Korea, Republic of, 110-744 Taiwan Local Institution Zhongzheng Dist., Taipei, Taiwan, 100 Collapse << |
实验方案
技术信息
CAS号 | 210644-62-5 | 储存条件 |
|
|
分子式 | C18H18N2O3 | 运输 | 蓝冰 | |
分子量 | 310.35 | 别名 | (Z)-SU6668;(Z)-TSU-68;NSC 702827;Orantinib;TSU 68;PDGFR Tyrosine Kinase Inhibitor VI |